Fate Therapeutics (FATE) grants RSUs and options to officer Cindy Tahl

Rhea-AI Filing Summary

Fate Therapeutics reported new equity awards to Chief Legal and Compliance Officer Cindy Tahl. On January 15, 2026, she was granted 100,000 shares of common stock at an acquisition price of $0.00, reported as an award of restricted stock units. These RSUs vest in four equal installments on January 8, 2027, 2028, 2029 and 2030, with each RSU converting into one share of common stock upon settlement. Following this grant, she beneficially owns 487,081 common shares directly.

She was also granted a stock option for 400,000 shares of common stock with an exercise price of $1.05 per share. This option vests in 36 equal monthly installments after January 1, 2026, becoming fully vested and exercisable on January 1, 2029, contingent on continued service with the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TAHL CINDY

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CA 92131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		A(1)		100,000	A	$0.00	487,081	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.05	01/15/2026		A		400,000		(2)	01/14/2036	Common Stock	400,000	$0.00	400,000	D

Explanation of Responses:

1. Award of restricted stock units ("RSUs") that vest with respect to 1/4th of the RSUs on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.

2. The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

Remarks:

Chief Legal and Compliance Officer

	/s/ Cindy Tahl	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for FATE on January 15, 2026?

The filing reports that officer Cindy Tahl received an award of 100,000 shares of common stock (via RSUs) at an acquisition price of $0.00 and a stock option for 400,000 shares with an exercise price of $1.05 per share.

How do the new RSUs for Fate Therapeutics (FATE) vest?

The 100,000 RSUs vest in four equal installments, with 1/4th vesting on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to Cindy Tahl’s continued service.

What are the terms of the new stock options granted at Fate Therapeutics (FATE)?

The stock option covers 400,000 shares of common stock at an exercise price of $1.05 per share. The shares vest in 36 equal monthly installments after January 1, 2026, and are fully vested and exercisable on January 1, 2029, if service continues.

How many Fate Therapeutics (FATE) shares does the reporting person own after these grants?

After the reported non-derivative transaction, 487,081 shares of common stock are shown as beneficially owned directly by Cindy Tahl.

Who is the insider receiving these equity awards at Fate Therapeutics (FATE)?

The reporting person is Cindy Tahl, who serves as Chief Legal and Compliance Officer of Fate Therapeutics, Inc.

Were these Fate Therapeutics (FATE) insider transactions open-market purchases or equity awards?

The reported transactions are equity awards: an RSU-based common stock award at $0.00 acquisition price and a stock option grant with a $1.05 exercise price, rather than open-market trades.